Veloxis Pharmaceuticals, Inc. v. Accord Healthcare, Inc. et al.

This patent infringement action is a Hatch-Waxman case initiated by a brand-name drug manufacturer to prevent market entry by a generic competitor. The plaintiff is Veloxis Pharmaceuticals, Inc., a U.S. subsidiary of the Japanese company Asahi Kasei and the holder of the New Drug Application (NDA) for Envarsus XR®. Envarsus XR is an extended-release tablet formulation of the immunosuppressant drug tacrolimus, used to prevent organ rejection in transplant patients. The defendants are Accord Healthcare, Inc., the U.S. subsidiary of Indian generic drug maker Intas Pharmaceuticals LTD, which is also a named defendant. Both Accord and Intas are operating companies focused on developing and marketing generic pharmaceuticals. The lawsuit was triggered by the defendants' submission of Abbreviated New Drug Application (ANDA) No. 217255 to the FDA, seeking approval to market a generic version of Envarsus XR before the expiration of Veloxis's patents.

The case was filed in the U.S. District Court for the District of Delaware, a popular venue for patent litigation, particularly for cases involving pharmaceutical patents and corporate litigation due to its experienced judiciary. The complaint, filed on July 7, 2022, initially asserted six patents, including U.S. Patent No. 9,549,918. The '918 patent, titled "Stabilized tacrolimus composition," covers pharmaceutical compositions of tacrolimus with a stabilizing agent to prevent degradation of the active ingredient upon storage. The case was assigned to Judge Joshua D. Wolson. A consent judgment was entered on January 24, 2024, enjoining Accord from making or selling its generic product until the patents-in-suit expire and dismissing all claims and counterclaims with prejudice.

This case is notable as part of a broader strategy by brand-name manufacturers to defend market exclusivity for key products against generic competition. The litigation highlights the commercial importance of Envarsus XR for Veloxis. The active ingredient, tacrolimus, is a narrow therapeutic index drug, meaning small differences in dose or formulation can lead to significant differences in therapeutic effect or toxicity, adding a layer of complexity to generic substitution. In fact, the FDA has previously raised concerns about Accord's immediate-release tacrolimus capsules (a different product), changing its therapeutic equivalence rating due to data suggesting it may deliver the drug at a higher peak concentration than the brand-name version, creating a risk of toxicity. Veloxis has engaged in similar litigation against other generic manufacturers, recently securing a settlement with Sun Pharmaceutical Industries Ltd. that blocks a generic version of Envarsus XR until May 2028.

Key Legal Developments and Outcome

This Hatch-Waxman litigation proceeded for approximately 18 months before resolving by consent judgment. The case did not reach a trial or a Markman hearing, with the parties instead reaching a settlement that resolved both the district court litigation and a parallel patent validity challenge at the Patent Trial and Appeal Board (PTAB).

Chronological Developments

• 2022-07-07: Complaint Filed
  Veloxis Pharmaceuticals, Inc. filed its patent infringement complaint against Accord Healthcare, Inc. and its parent company, Intas Pharmaceuticals LTD. The suit was triggered by Accord's filing of Abbreviated New Drug Application (ANDA) No. 217255, which sought FDA approval to market a generic version of Veloxis's Envarsus XR® (tacrolimus extended-release tablets). The complaint, filed in the District of Delaware, alleged that Accord's proposed generic product would infringe six Veloxis patents: U.S. Patent Nos. 8,993,002; 9,180,100; 9,549,918; 9,814,688; 10,238,622; and 11,304,917. The filing of the lawsuit within the 45-day statutory window automatically stayed the FDA's approval of Accord's ANDA for up to 30 months. (Case No. 1:22-cv-00909, D.I. 1).

• 2022-09-09: Answer and Counterclaims Filed
  Accord and Intas filed their answer to the complaint, denying infringement and asserting that the patents-in-suit were invalid. They also filed counterclaims seeking a declaratory judgment of non-infringement and invalidity for all six asserted patents. (Case No. 1:22-cv-00909, D.I. 15).

• 2023-01-20: Scheduling Order Entered
  After the parties conferred on a proposed schedule, the court entered a scheduling order setting key deadlines for the litigation. The order scheduled a Markman hearing for claim construction for October 20, 2023, discovery cut-off for January 19, 2024, and a 5-day jury trial to begin on June 10, 2024. (Case No. 1:22-cv-00909, D.I. 25).

• 2023-05-17: Parallel PTAB IPR Petition Filed
  In a move to challenge the validity of the core patent on a separate front, Accord Healthcare filed an Inter Partes Review (IPR) petition with the PTAB, challenging all claims of U.S. Patent No. 9,549,918. This is a common tactic used by generic challengers to pressure the patent holder and potentially invalidate the patent outside of the district court process. The IPR was docketed as case number IPR2023-00906.

• 2023-07-13: Motion to Stay Litigation Denied
  Following its IPR filing, Accord moved to stay the district court litigation pending the PTAB's decision on whether to institute the IPR and, if instituted, pending a final written decision. Accord argued that a stay would conserve judicial and party resources, as an invalidity finding by the PTAB could dispose of a significant portion of the district court case. Veloxis opposed the stay. Judge Wolson denied the motion, a common outcome in the District of Delaware where judges often prefer to keep Hatch-Waxman cases moving forward to trial. The denial meant the district court case would proceed in parallel with the PTAB proceeding.

• 2023-11-20: PTAB Institutes Inter Partes Review
  The PTAB issued a decision instituting trial on Accord's IPR petition, finding that Accord had established a "reasonable likelihood" that it would prevail in proving that at least one claim of the '918 patent was invalid as obvious. This decision was a significant development, as it meant the patent would face a full validity trial before the administrative patent judges at the PTAB, putting pressure on Veloxis to settle.

• 2024-01-23: Settlement and Joint Motion to Terminate IPR
  With the IPR trial underway and the district court case proceeding towards trial, the parties reached a global settlement. Veloxis, Accord, and Intas jointly filed a motion to terminate the IPR proceeding, stating they had resolved their dispute. As part of the settlement, Accord agreed to withdraw its validity challenge at the PTAB.

• 2024-01-24: Consent Judgment and Dismissal
  The day after settling the IPR, the parties filed a stipulation for the entry of a consent judgment and dismissal in the district court. Judge Wolson entered the order, which permanently enjoined Accord and Intas from manufacturing or selling their generic tacrolimus product until the expiration of the patents-in-suit. The judgment dismissed all of Veloxis's infringement claims and all of the defendants' invalidity counterclaims with prejudice. The specific terms of the settlement, including the licensed entry date for the generic product, were not publicly disclosed in the court filings.

• 2024-01-25: PTAB Terminates IPR Proceeding
  Following the parties' joint motion, the PTAB officially terminated the IPR2023-00906 proceeding, bringing the parallel validity challenge to a close.

This outcome represents a victory for Veloxis, as it resolved the litigation and the PTAB challenge, thereby protecting the market exclusivity for Envarsus XR from Accord's generic competition for a defined period.

Based on court filings and legal directories, the following counsel represented the plaintiff, Veloxis Pharmaceuticals, Inc., in this matter. The legal team comprised attorneys from the Chicago-based intellectual property boutique McDonnell Boehnen Hulbert & Berghoff LLP, who likely served as lead counsel, and the Delaware firm Morris, Nichols, Arsht & Tunnell LLP, which served as local counsel.

Lead Counsel

• Name: Paul H. Berghoff

  • Role: Lead Counsel
  • Firm: McDonnell Boehnen Hulbert & Berghoff LLP (MBHB), Chicago, IL.
  • Experience Note: A founding partner of MBHB, Berghoff has over three decades of experience as lead trial counsel in complex pharmaceutical and medical device patent litigation.

• Name: Daniel A. Boehnen

  • Role: Lead Counsel
  • Firm: McDonnell Boehnen Hulbert & Berghoff LLP (MBHB), Chicago, IL.
  • Experience Note: A founding partner of MBHB, Boehnen's practice focuses on trials and appeals in disputed patent matters, and he has been recognized as a top IP litigator for nearly two decades.

• Name: Michael K. Nutter

  • Role: Of Counsel
  • Firm: McDonnell Boehnen Hulbert & Berghoff LLP (MBHB), Chicago, IL. (Note: Nutter has since moved firms, but was likely with MBHB during this case's primary litigation phase. Public records show a later affiliation with Taft Law.)
  • Experience Note: Nutter is a first-chair trial lawyer and registered patent attorney specializing in Hatch-Waxman Act pharmaceutical patent litigation for generic and brand-name companies.

Local Counsel

• Name: Jack B. Blumenfeld

  • Role: Lead Local Counsel
  • Firm: Morris, Nichols, Arsht & Tunnell LLP, Wilmington, DE.
  • Experience Note: Described as a "dean of the Delaware bar," Blumenfeld has 40 years of experience and offers renowned expertise in high-stakes pharmaceutical and technology patent litigation.

• Name: Megan E. Dellinger

  • Role: Local Counsel
  • Firm: Morris, Nichols, Arsht & Tunnell LLP, Wilmington, DE.
  • Experience Note: Dellinger's practice focuses on patent infringement litigation, particularly in the pharmaceutical and chemical arts, and includes experience in inter partes review (IPR) proceedings.

Counsel for Defendants

The defendants, Accord Healthcare, Inc. and Intas Pharmaceuticals LTD, were represented by attorneys from the law firms Paul, Weiss, Rifkind, Wharton & Garrison LLP and Farnan LLP.

Paul, Weiss, Rifkind, Wharton & Garrison LLP

• David M. Maiorana (Lead Counsel) - Partner, Wilmington, DE. Maiorana is a seasoned patent litigator with extensive experience in Hatch-Waxman cases, representing pharmaceutical and biotechnology companies.
• Megan E. Dellinger (Of Counsel) - Associate, Wilmington, DE. Dellinger focuses her practice on patent litigation, particularly within the pharmaceutical sector.

Farnan LLP

• Brian E. Farnan (Local Counsel) - Partner, Wilmington, DE. As a former federal magistrate judge for the District of Delaware, Farnan has deep experience in the district's local patent rules and practices, frequently serving as Delaware counsel in complex patent disputes.
• Michael J. Farnan (Local Counsel) - Partner, Wilmington, DE. He regularly acts as Delaware counsel in patent infringement litigation, representing a wide array of clients in the district.

The appearance of counsel for the defendants was officially filed on August 29, 2022 (D.I. 8). This legal team defended Accord and Intas against the infringement claims brought by Veloxis until the parties reached a settlement, culminating in a consent judgment entered on January 24, 2024.